Rifaximin-based regimens for eradication of Helicobacter pylori: A pilot study

Digestive Diseases

Volumn 24, Issue 1-2, 2006, Pages 195-200

  Gasbarrini, Antonio ^a   Lauritano, Ernesto Cristiano ^a   Nista, Enrico Celestino ^a   Candelli, Marcello ^a   Gabrielli, Maurizio ^a   Santoro, Michele ^a   Zocco, Maria Assunta ^a   Cazzato, Alessia ^a   Finizio, Rosalba ^a   Ojetti, Veronica ^a   Cammarota, Giovanni ^a   Gasbarrini, Giovanni ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Clarithromycin; Helicobacter pylori; Levofloxacin; Rifaximin

Indexed keywords

CARBON 13; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; RIFAXIMIN;

ARTICLE; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; EPIGASTRIC PAIN; ERADICATION THERAPY; EVALUATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ITALY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TASTE DISORDER; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; PILOT PROJECTS; RIFAMYCINS; TREATMENT OUTCOME;

EID: 33644556701     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090330     Document Type: Article

References (38)

1. Vaira D, Mignoli M, Mule P, Holton J, Menegatti M, Vergura M, Biasco G, Conte R, Logan RP, Barbara L: Prevalence of peptic ulcer in Helicobacter pylori-positive blood donors. Gut 1994;35:309-312.
2. Parsonnet J, Fridman GD, Orentreich N, Vogelman H: Risk of gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301.
3. The Eurogast Study Group: An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-1362.
4. Gasbarrini A, Carloni E, Gasbarrini G, Chisholm SA: Helicobacter Pylori and extragastric diseases-other Helicobacters. Helicobacter 2004;9(suppl 1):57-66.
5. Vazquez Romero M, Bermejo San Jose F, Boixeda de Miquel D, Martin de Argila, Prados C, Boixeda de Miquel P, Foruny Olcina JR: Chronic urticaria and Helicobacter pylori. Med Clin (Barc) 2004;122:573-575.
6. Franchini M, Verneri D: Helicobacter pylori infection and immune thrombocytopenic purpura: an update. Helicobacter 2004;9:342-346.
7. Candelli M, Carloni E, Nista EC, Cazzato IA, Pignataro G, Rigante D, Gasbarrini A: Helicobacter pylori eradication and acne rosacea resolution: cause-effect or coincidence? Dig Liver Dis 2004;36:163.
8. Gabrielli M, Fiore G, Candelli M, Giacovazzo M, Pola P, Gasbarrini G, Gasbarrini A: Chronic Helicobacter pylori infection and migraine: a case-control study. Headache 2002;42:236-237.
9. Gasbarrini A, Gabrielli M, Fiore G, Candelli M, Bartolozzi F, De Luca A, Cremonini F, Franceschi F, Di Campli C, Armuzzi A, Ojetti V, Serricchio M, Pola R, Gasbarrini G, Giacovazzo M, Pola P: Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia 2000;20:561-565.
10. Kounturas J, Zavos C, Chatzopoulos D: Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. Med Hypotheses 2004;62:378-381.
11. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
12. Bazzoli F, Zagari RM, Fossi S: Short-term low-dose therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-777.
13. Bock H, Koop H, Lehn N, Heep M: Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000;31:222-225.
14. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A: Rifabutin-based rescue therapy for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316.
15. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A: Letter to editors: Rifabutin-based Helicobacter pylori eradication rescue therapy. Aliment Pharmacol Ther 2001;15:143.
16. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antimicrobial: pharmacology and clinical use. Chemotherapy 2005;51(suppl 1):36-66.
17. Jiang ZD, DuPont HL: Rifaximin: in vitro and in vivo antibacterial activity: a review. Chemotherapy 2005;51(suppl 1):67-72.
18. Ericsson CD, DuPont HL: Rifaximin in the treatment of infectious diarrhea. Chemotherapy 2005;51(suppl 1):73-80.
19. Papi C, Koch M, Capurso L: Management of diverticular disaease: is there room for rifaximin? Chemotherapy 2005;51(suppl 1):110-114.
20. Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M: Inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 2005;51(suppl 1):96-102.
21. Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M: Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 2005;51(suppl 1):90-95.
22. Nichols RL, Choe EU, Weldon CB: Mechanical and antibacterial bowel preparation in colon and rectal surgery. Chemotherapy 2005;51(suppl 1):115-121.
23. Di Stefano M, Corazza GR: Treatment of small intestinal bacterial overgrowth and related symptoms by rifaximin. Chemotherapy 2005;51(suppl 1):103-109.
24. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-35.
25. Megraud F, Bouffant F, Camou Juncas C: In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994;13:184-186.
26. Holton J, Vaira D, Menegatti M, Barbara L: The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995;35:545-549.
27. De Giorgio R, Stanghellini V, Barbara G, Guerrini S, Ferrieri A, Corinaldesi R: Rifaximin and Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 1997;1:105-110.
28. Dell'Anna A, Azzarone P, Ferrieri A: A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. Eur Rev Med Pharmacol Sci 1999;3:105-110.
29. Vaira D, Menegatti M, Miglioli M, Ferrieri A, et al: Rifaximin suspension for the eradication of Helicobacter pylori. Curr Ther Res 1997;58:300-308.
30. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, Stratton CW, Drnec J, Prokocimer P, Siepman N: Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-bind trial. Am J Gastroenterol 1993;88:1860-1864.
31. Quesada M, Sanfeliu I, Junquera F, Segura F, Calvet X: Evaluation of Helicobacter pylori susceptibility to rifaximin [in Spanish]. Gastroenterol Hepatol 2004;27:393-396.
32. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G: Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-1343.
33. Di Caro S, Assunta Zocco M, Cremonini F, Candelli M, Nista EC, Bartolozzi F, Armuzzi A, Cammarota G, Santarelli L, Gasbarrini A: Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002;14:1309-1312.
34. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carloni E, Cammarota G, Gasbarrini G, Gasbarrini A: Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-633.
35. Cliodna McNulty AM, Dent JC, Ford GA, Wilkinson SP: Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988;22:729-738.
36. Munoz DJB, Tasman Jones C, Pybus J: Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus. Gut 1992;33:592-596.
37. Huynh HQ, Couper RT, Tran CD, Moore L, Kelso R, Butler RN: N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci 2004;49:1853-1861.
38. Gotoh A, Akamatsu T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, Ishida K, Ikeno T, Sugiyama A, Kawakami Y, Ota H, Katsuyama T: Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 2002;7:183-191.